Cybrexa Therapeutics

Cybrexa Therapeutics is a privately held biotechnology company based in New Haven, Connecticut. The company employs 6 people. Cybrexa Therapeutics focuses on developing novel antigen-independent peptide drug conjugates (ADCs) to combat various cancer types, including ovarian, breast, and non-small cell lung cancer. Their alphalex™ technology platform utilizes pHLIP® peptides, which target acidic cell surfaces, to deliver potent anticancer treatments. Cybrexa's lead candidate, CBX-12, has shown promising results in early clinical trials for patients with metastatic cancer. What sets Cybrexa apart is their pioneering alphalex™ technology. This platform offers a unique antigen-independent approach to targeted drug delivery in oncology, potentially revolutionizing the standard of care. For inquiries or more information, visit Cybrexa Therapeutics' website at www.cybrexa.com.